Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyLong-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study

The BILCAP study established capecitabine as the adjuvant standard of care for patients after curatively resected biliary tract cancer (BTC). This publication presents the long-term data of that study. In the intention-to-treat analysis, the median OS was 49.6 months in the capecitabine group compared with 36.1 months in the observation group.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form